LUMO Lumos Pharma, Inc.: Operatsion rentabellik

LUMO (Lumos Pharma, Inc.) - kompaniyaning tovar belgisi

Lumos Pharma, Inc. (LUMO) kompaniyasi tadqiqot va ishlanmalar (R&D) xarajatlari kelajakdagi monopoliyaga asos soladigan patent modeliga tayanadi. Operatsion marja trekkeri daromadli tendentsiyalarni qayd etadi va ushbu ko'rsatkich hozirda -1647.60 ga yetmoqda. O'sish istiqbollari endokrin patologiyalar terapiyasida LUM-201 dori vositasining muvaffaqiyatiga bog'liq. Biroq, joriy savdoning yo'qligi va kechki bosqich sinovlari uchun xarajatlarning ortishi biznesni kengaytirishga vaqtincha to'sqinlik qilmoqda.

Lumos Pharma Inc (LUMO): Operatsion rentabellik 04.07.2022dan 21.12.2024gacha

Lumos Pharma, Inc. kompaniyasining tahliliy kesimlari

- narx va narxlar bo'yicha konsensus prognoz:
Kompaniyaning fundamental tahlili:LUMO, Lumos Therapeutics
Lumos Pharma, Inc. asosiy tovari

Lumos Pharma, Inc. (LUMO) kredit sifatini baholash uchun tahlilchi operatsion marja ko'rsatkichiyidan foydalanadi, u asosiy biznesning samaradorligini aniqlash uchun operatsion foydaning umumiy daromadga nisbatini hisoblaydi. Kompaniya hozirda endokrin dori vositalari uchun klinik sinovlar bosqichida bo'lganligi sababli, ushbu grafik bozor narxlarini emas, balki ishlab chiqish xarajatlarini aks ettiradi va ushbu ko'rsatkichni mahsulot tijoratlashtirilishidan oldin kapital xarajatlarini monitoring qilish vositasiga aylantiradi.

Raqobatchilar tahlili

Operatsion rentabellik Ascendis|Madrigal Corp (MDGL) - Operatsion faoliyat rentabelligi|Operatsion rentabellik corcept.com (CORT)|Sotuvning operatsion marjasi rhythmtx.com RYTM|Operatsion marja AKRO (akerotx.com)|MTSR - Sotuvning operatsion marjasi|MLTX - Operatsion rentabellik|Operatsion foyda normasi CRNX (Crinetics Pharma)|NAMS (newamsterdampharma.com) - Sotuvning operatsion marjasi|SLNO (Soleno Therapeutics) - Operatsion rentabellik|FOLD (Amicus Therapeutics Inc) - Operatsion marja|Sotuvning operatsion rentabelligi 89bio Corp ETNB|Operatsion rentabellik Agios Corp (AGIO)|Sotuvning operatsion marjasi Structure Therapeutics GPCR|MiMedx - Sotuvning operatsion marjasi|Operatsion marja Rezolute RZLT|LXRX - Operatsion rentabellik|Operatsion faoliyat rentabelligi MBX Biosciences MBX|ALT: Operatsion marja|Aardvark Therapeutics Inc (AARD) - Operatsion marja|SGMT (Sagimet Biosciences) - Operatsion marja|Operatsion marja BioAge Labs, Inc.|Operatsion rentabellik Biomea Fusion Inc (BMEA)|QNCX - Sotuvning operatsion rentabelligi|Operatsion marja GUTS (Fractyl Health Inc.)|vtvtherapeutics.com (VTVT) - Sotuvning operatsion rentabelligi|ATPC - Operatsion rentabellik|PLUR: Operatsion rentabellik|SYBX (Synlogic, Inc.) - Sotuvning operatsion marjasi|LPCN - Operatsion faoliyat rentabelligi|MTNB (Matinas BioPharma Holdings Inc.) - Operatsion marja|Sotuvning operatsion rentabelligi Spruce Biosciences Inc. SPRB|Sotuvning operatsion marjasi GLTO (Galecto Corp)|Operatsion marja Carmell (CTCX)|Operatsion marja ONVO (organovo.com)|Operatsion foyda bo'yicha marjinallik Radius Health